Vir Biotechnology CEO Marianne De Backer at JPM20 (Jeff Rumans)

Vir’s GSK-al­lied flu pre­ven­tion an­ti­body fails PhII, sink­ing shares and late-stage hope

Vir Biotech­nol­o­gy’s in­fluen­za an­ti­body has failed a crit­i­cal Phase II clin­i­cal tri­al, which could spell bad news for its part­ner GSK, who has the op­tion …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.